Cancer Genetics, Inc. (CGI) has been selected by H3 Biomedicine to provide clinical biomarker services for H3’s lead oncology drug candidate H3B-8800, an orally available selective small molecule being developed as an anticancer agent for the potential treatment of select hematologic cancers. CGI will also support biomarker discovery and development for H3’s early-stage candidates.
 
H3’s SF3B1 clinical program targets deregulated RNA homeostasis in cancer through RNA splicing modulation. This clinical study expands H3’s existing drug discovery efforts around targeting SF3B1 and splice modulation to design novel treatments for various cancers.

CGI will employ its oncology-focused menu and biomarker development expertise using various platforms, including next generation sequencing, RNA expression-profiling, and other technologies. CGI expects the trial to continue for the next several years, and may potentially enable an expedited, and more efficient development timeline.

“We are very pleased to partner with Cancer Genetics and look forward to implementing their established oncology biomarker and molecular testing platforms,” said Peter Smith Ph.D., vice president, Biology at H3 Biomedicine. “The important insights we may gain through this collaboration will ultimately help us advance our clinical program.”

“Our work with H3Bio is a testament to our ability to integrate new innovations and global trial execution for global biotech and pharma companies in a disease focused manner,” said Panna Sharma, chief executive officer and president of CGI. “Our teams are working very well together and are tremendously motivated by the opportunity to help our partner in the implementation of the biomarker program that can accelerate the delivery of breakthrough precision medicines for cancers.”